Summary Some studies have suggested that the S allele of the MYCL oncogene, which results from an intragenic EcoRI restriction fragment length polymorphism (RFLP), may be associated with cancer susceptibility. In addition, this allele has also been linked to metastases and adverse survival in certain cancers, although studies of lung cancer patients from different populations have yielded controversial results. We studied 108 cases of surgical resected non-small-cell lung cancer (NSCLC) and found no evidence that MYCL gentotypes were associated with tumour progression or a worse prognosis. However, the presence of loss of heterozygosity (LOH) In terms of cancer susceptibility, the S allele of MYCL was more common in patients with non-Hodgkin's lymphoma (Crossen et al., 1994) , and male patients with bone and softtissue sarcomas . In addition, the SS genotype was more frequent in colorectal cancer patients than in young blood donor controls (Young et al., 1994). However, the cancer-susceptibility model is controversial, as the SS genotype appears to protect against hepatocellular cancer (Taylor et al., 1993) , and the S allele was not increased in patients with lung cancer (Tamai et al., 1990; Weston et al., 1992 Weston et al., , 1994 , breast cancer (Champeme et al., 1992) or lymphoma/leukaemia (Chenevix-Trench et al., 1989) .
In many western countries, including Australia, lung cancer is the commonest malignancy in males and the largest cause of cancer deaths. While conventional management has not dramatically changed lung cancer mortality rates, molecular developments have expanded our understanding of the mechanisms leading to lung tumorigenesis, leading to efforts to use these discoveries to optimise the treatment of lung cancer.
A potential molecular marker associated with cancer susceptibility, as well as metastases and adverse survival, is the MYCL oncogene. This gene contains an EcoRI restriction fragment length polymorphism (RFLP), which allows genotyping into either L or S alleles.
In terms of cancer susceptibility, the S allele of MYCL was more common in patients with non-Hodgkin's lymphoma (Crossen et al., 1994) , and male patients with bone and softtissue sarcomas . In addition, the SS genotype was more frequent in colorectal cancer patients than in young blood donor controls (Young et al., 1994) . However, the cancer-susceptibility model is controversial, as the SS genotype appears to protect against hepatocellular cancer (Taylor et al., 1993) , and the S allele was not increased in patients with lung cancer (Tamai et al., 1990; Weston et al., 1992 Weston et al., , 1994 , breast cancer (Champeme et al., 1992) or lymphoma/leukaemia (Chenevix-Trench et al., 1989) .
As regards tumour progression, Kawashima et al. (1988, 1992) , in an initial study followed by a larger study involving 252 Japanese lung cancer patients, showed that the S allele predisposed to metastases and adverse prognosis. Conversely, this association has not been found in Caucasian (Norwegian and North American) lung cancer populations (Tamai et al., 1990; Tefre et al., 1990; Weston et al., 1992 Weston et al., , 1994 (Fong et al., 1995) .
The MYCL gene was discovered as two additional DNA fragments of 10.0 kb and 6.6 kb when the MYC gene was used to probe EcoRI digested human genomic DNA (Nau et al., 1985) . These fragments represent a RFLP at the MYCL locus, situated in the second intron (Kaye et al., 1988) . This RFLP can also be revealed with polymerase chain reaction (PCR) using primers, which flank a 267 bp DNA fragment containing this polymorphism, followed by EcoRI digestion to yield the uncut L allele or the cut S allele of 142 and 125 bp (Tamai et al., 1990) . DNA from tumour tissue and corresponding normal lung of each patient was examined for this RFLP. Standard PCR conditions were used with restriction enzyme digestion performed according to manufacturer's instructions. PCR products were electrophoretically fractionated in 12% polyacrylamide gels with 10% glycerol and visualised after ethidium bromide staining.
Tumour DNA was also examined for LOH using PCR to amplify a highly polymorphic Alu variable polyA microsatellite marker 16 (Figure 1) . The L and S allele frequencies were 0.523 and 0.477 respectively, similar to the frequencies reported by Nau et al. (1985) , and the genotypes were found to be in accord with Hardy -Weinberg equilibrium (P=0.987, x2).
There was no difference between the genotypes of the two major NSCLC subtypes; squamous cell carcinoma (SCC) and adenocarcinoma. There was also no correlation of the genotypes with either age, sex, smoking history, T, N or TNM stage (Table I) .
Furthermore, neither the S allele (LS and SS genotypes) nor homozygosity for the S allele (SS genotype) was associated with T, N or TNM stage (Table II (Fong et al., 1995) . Twenty-three of these 85 (27%) informative cases showed LOH at the MYCL locus (Figure 2 ). Weston et al., 1992 Weston et al., , 1994 , are in direct contrast to the Japanese studies (Kawashima et al., 1988 (Kawashima et al., , 1992 . While it is possible that the adverse clinicopathological association of the S allele only applies to Japanese lung cancer patients, studies of other cancers within this population have shown conflicting results, thereby indicating possible tissue specificity. For instance, the S allele was associated with metastases in renal (Kakehi and Yoshida, 1989) and gastric cancers ), but not colorectal or breast cancers (Ikeda et al., 1988; Ishizaki et al., 1990) in Japanese patients. Several studies of cancers other than lung in non-Japanese populations have also linked the S allele with tumour progression. The S allele was associated with tumour size and a lack of differentiation in Indian oral cancer patients (Saranath et al., 1990) , and lung metastases in Caucasian breast cancer patients (Champeme et al., 1992) . Furthermore, the SS genotype was associated with a worsening clinicopathological stage in Australian colorectal patients recruited from the same region in Queensland as our cases (Young et al., 1994) .
On the other hand, independent studies have now consistently shown a lack of an adverse impact for the S allele in a variety of Caucasian lung cancer patients, questioning the validity of these observations. While an alternative explanation is that these studies were too insensitive to detect an association, another possibility is that the RFLP within certain populations (ethnic groups) may be in linkage disequilibrium with a gene that is critical to tumour progression and survival. In this regard, it has been demonstrated that the frequency of the EcoRI RFLP varies by race (Weston et al., 1994) . We thus investigated whether LOH, a hallmark feature of tumour-suppressor genes, was present in this chromosomal region.
Although LOH at the lp32 MYCL locus was not found in Kawashima's initial study (Kawashima et al., 1988) , LOH at lp has since been described in approximately 15-18% of NSCLCs (Sato et al., 1994; Tsuchiya et al., 1992) . Furthermore, new highly polymorphic microsatellite markers have also improved LOH analysis. Using such a marker just upstream of MYCL (Makela et al., 1992) , we found that 23 of the 85 (27%) informative cases showed LOH. It should be noted that while the presence of gene amplification may cause false-positive LOH results by microsatellite analysis (Nagai et al., 1994) , this is an unlikely confounder here because MYCL is rarely (< 1%) amplified in NSCLC (Bergh, 1990; Shiraishi et al., 1989; Slebos et al., 1989; Yokota et al., 1988) .
As for clinicopathological features (Table I) , the frequency of LOH was significantly higher in SCCs (13/34, 38%) compared with the adenocarcinomas (5/38, 13%; P=0.014, x2 (Grundy et al., 1994) , phaeochromocytoma (Tsutsumi et al., 1989) and colon cancer (Laurent-Puig et al., 1992) . More evidence comes from the recent report that allelic loss of 1 p was a strong prognostic factor in patients with neuroblastoma, independent of age and stage (Caron et al., 1996) . In addition, somatic cell hybrid experiments have shown that the loss of chromosome 1 was associated with the malignant phenotype (Stoler and Bouck, 1985) .
As we only investigated LOH at MYCL and did not specifically map the critical region of genetic loss, it is possible that MYCL is not the target gene but may just be deleted coincidentally. For instance, the critical region of loss appears to be distal to MYCL in colorectal cancers (Leister et al., 1990) , whereas multiple areas of LOH have been identified in breast cancer, including one just proximal to MYCL (Hoggard et al., 1995) . Consequently, candidate genes include p18 at lp32 (Guan et al., 1994) , as well as other lp genes such as DAN (Enomoto et al., 1994) , RAPlGAI (Weiss et al., 1994) and PITSLRE (Lahti et al., 1994) . The increasing availability of closely spaced microsatellite markers should, however, facilitate the localisation and identification of the candidate NSCLC tumour-suppressor gene in the minimally deleted chromosomal region (Gyapay et al., 1994) .
